Across the recent three months, 22 analysts have shared their insights on Edwards Lifesciences EW, expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 7 | 5 | 10 | 0 | 0 |
| Last 30D | 0 | 0 | 0 | 0 | 0 |
| 1M Ago | 4 | 4 | 10 | 0 | 0 |
| 2M Ago | 1 | 0 | 0 | 0 | 0 |
| 3M Ago | 2 | 1 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $87.23, along with a high estimate of $110.00 and a low estimate of $70.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 11.29%.
Analyzing Analyst Ratings: A Detailed Breakdown
An in-depth analysis of recent analyst actions unveils how financial experts perceive Edwards Lifesciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matt Miksic | Barclays | Lowers | Overweight | $90.00 | $101.00 |
| David Roman | Goldman Sachs | Lowers | Buy | $91.00 | $107.00 |
| Joshua Jennings | TD Cowen | Lowers | Hold | $70.00 | $100.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Overweight | $90.00 | $99.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $76.00 | $91.00 |
| Pito Chickering | Deutsche Bank | Lowers | Buy | $85.00 | $103.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $85.00 | $101.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $82.00 | $110.00 |
| Rick Wise | Stifel | Lowers | Hold | $70.00 | $85.00 |
| Suraj Kalia | Oppenheimer | Lowers | Outperform | $90.00 | $100.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $77.00 | $85.00 |
| Adam Maeder | Piper Sandler | Lowers | Neutral | $73.00 | $88.00 |
| Travis Steed | B of A Securities | Lowers | Neutral | $75.00 | $105.00 |
| Robbie Marcus | JP Morgan | Lowers | Neutral | $72.00 | $105.00 |
| David Rescott | Baird | Lowers | Neutral | $70.00 | $102.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $110.00 | $105.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $106.00 | $105.00 |
| Vijay Kumar | Evercore ISI Group | Raises | In-Line | $91.00 | $89.00 |
| David Roman | Goldman Sachs | Announces | Buy | $107.00 | - |
| Joanne Wuensch | Citigroup | Raises | Buy | $105.00 | $98.00 |
| Pito Chickering | Deutsche Bank | Raises | Buy | $103.00 | $86.00 |
| Matt Miksic | Barclays | Raises | Overweight | $101.00 | $100.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Edwards Lifesciences. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Edwards Lifesciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into Edwards Lifesciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
Discovering Edwards Lifesciences: A Closer Look
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US
Edwards Lifesciences's Financial Performance
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Challenges: Edwards Lifesciences's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -13.28%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Edwards Lifesciences's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 26.43%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.03%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Edwards Lifesciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.69% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.09.
Analyst Ratings: Simplified
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
